已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

安慰剂 医学 双盲 内科学 物理疗法 替代医学 病理
作者
Zifeng Yang,Zhengtu Li,Yangqing Zhan,Zhengshi Lin,Zhonghao Fang,Xiaowei Xu,Lin Lin,Haijun Li,Zejun Lin,Changyuan Kang,Jingyi Liang,Shiwei Liang,Yongming Li,Shaoqiang Li,Xinyun Yang,Feng Ye,Nanshan Zhong,Ping Zhang,Xiaoguang Li,Jie Peng
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (5): 535-545 被引量:28
标识
DOI:10.1016/s1473-3099(23)00743-0
摘要

Summary

Background

Onradivir (ZSP1273) is a novel anti-influenza A virus inhibitor. Preclinical studies show that onradivir can inhibit influenza A H1N1 and H3N2 replication and increase the survival rate of infected animals. In this study, we aimed to evaluate the safety and efficacy of three onradivir dosing regimens versus placebo in outpatients with acute uncomplicated influenza A virus infection.

Methods

We did a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial at 20 clinical sites in China. Eligible participants were adults (18–65 years) with an influenza-like illness screened by rapid antigen testing at the first clinical visit, had the presence of a fever (axillary temperature ≥38·0°C), and had the presence of at least one moderate systemic and one respiratory symptom within 48 h of symptom onset. Patients were excluded if they were pregnant, allergic to onradivir, or had received any influenza antiviral medication within 7 days before enrolment. Participants were randomly assigned (1:1:1:1) into four groups by an interactive web response system: onradivir 200 mg twice per day group, onradivir 400 mg twice per day group, onradivir 600 mg once per day group, and a matching placebo group. A 5-day oral treatment course was initiated within 48 h after symptoms onset. The primary outcome was the time to alleviate influenza symptoms in the modified intention-to-treat population. Safety was a secondary outcome. We evaluated the patients' self-assessed severity of seven influenza symptoms on a 4-point ordinal scale, and the treatment-emergent adverse events in all patients. This trial is registered with ClinicalTrials.gov, number NCT04024137.

Findings

Between Dec 7, 2019, and May 18, 2020, a total of 205 patients were screened; of whom, 172 (84%) were randomly assigned to receive onradivir (n=43 in the 200 mg twice per day group; n=43 in the 400 mg twice per day group; and n=43 in the 600 mg once per day group), or placebo (n=42). Median age was 22 years (IQR 20–26). All three onradivir groups showed decreased median time to alleviate influenza symptoms (46·92 h [IQR 24·00–81·38] in the 200 mg twice per day group, 54·87 h [23·67–110·62] in the 400 mg twice per day group, and 40·05 h [17·70–65·82] in the 600 mg once per day) compared with the placebo group (62·87 h [36·40–113·25]). The median difference between the onradivir 600 mg once per day group and the placebo group was –22·82 h (p=0·0330). The most frequently reported treatment-emergent adverse event was diarrhoea (71 [42%] of 171), ranging from 33–65% of the patients in onradivir-treated groups compared with 10% in the placebo group; no serious adverse events were observed.

Interpretation

Onradivir showed a safety profile comparable to placebo, as well as higher efficacy than placebo in ameliorating influenza symptoms and lowering the viral load in adult patients with uncomplicated influenza infection, especially the onradivir 600 mg once per day regimen.

Funding

National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine, National Natural Science Foundation of China, Guangdong Science and Technology Foundation, Guangzhou Science and Technology Planning Project, Emergency Key Program of Guangzhou Laboratory, Macao Science and Technology Development Fund, and Guangdong Raynovent Biotech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
ddd完成签到,获得积分10
1秒前
牧青发布了新的文献求助10
1秒前
2秒前
pericles发布了新的文献求助10
3秒前
我是老大的应助被zikang采纳,获得10
4秒前
4秒前
自然的小蝴蝶完成签到 ,获得积分10
5秒前
爆米花的应助被小萝卜采纳,获得10
5秒前
司闻完成签到,获得积分10
5秒前
大爱人生完成签到 ,获得积分10
5秒前
鸢也发布了新的文献求助10
5秒前
8秒前
8秒前
9秒前
逢考必过完成签到,获得积分10
9秒前
WLJlele发布了新的文献求助10
11秒前
bkagyin的应助被苹果曼波采纳,获得10
11秒前
li发布了新的文献求助10
13秒前
13秒前
academician发布了新的文献求助10
14秒前
朱子涵完成签到,获得积分10
14秒前
科研通AI6.2的应助被magicstool采纳,获得50
14秒前
Arthurllee发布了新的文献求助10
15秒前
科研通AI6.3的应助被uu采纳,获得10
15秒前
Ava的应助被美满懿轩采纳,获得10
16秒前
16秒前
敏感毒娘发布了新的文献求助10
17秒前
牧青发布了新的文献求助10
18秒前
哈哈哈哈哈哈完成签到 ,获得积分10
19秒前
academician完成签到,获得积分10
19秒前
jes发布了新的文献求助10
20秒前
今后的应助被Audrey采纳,获得10
20秒前
朱子涵发布了新的文献求助10
21秒前
科研通AI6.2的应助被mont采纳,获得10
21秒前
思源的应助被mmyhn采纳,获得10
21秒前
NexusExplorer的应助被mont采纳,获得10
21秒前
万能图书馆的应助被mont采纳,获得20
21秒前
余香的应助被mont采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189671
求助须知:如何正确求助?哪些是违规求助? 9576938
关于积分的说明 21850391
捐赠科研通 7787625
什么是DOI,文献DOI怎么找? 3435756
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482624